Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase IIIb, Prospective, Interventional, Multicentre, 3-year Study to Explore the Long-term Evolution of Sign and Symptoms, and Occurence of Complications in Dry Eye Patients With Severe Keratitis Receiving Ikervis® (1mg/mL Ciclosporin)

NCT04144413 is registered in ClinicalTrials.gov with Santen SAS as lead sponsor.

NCT NCT04144413
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04144413 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase IIIb, Prospective, Interventional, Multicentre, 3-year Study to Explore the Long-term Evolution of Sign and Symptoms, and Occurence of Complications in Dry Eye Patients With Severe Keratitis Receiving Ikervis® (1mg/mL Ciclosporin)
Lead sponsor
Santen SAS
Phase
Phase 3
Overall status
Completed
Start date
May 31, 2019
Completion date
July 14, 2023
Enrollment
350 (actual)
Sites
45

Conditions

As the registry lists them; a condition with its own page is linked.

dry eye disease with severe keratitis